Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1654 companies, A–Z).
Arrowhead Pharmaceuticals refinanced its senior secured term loans on November 2, 2026, replacing a 15.0% payment-in-kind facility with a $400.0 million term loan at three-month Term SOFR plus 5.50% that matures November 2, 2031. The existing loans were repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, a discount of about $68 million from the 2.0x MOIC payment otherwise owed, and the new terms remove required prepayments from plozasiran sales and licensing proceeds. For shareholders, the filing shows lower interest cost, a longer maturity and fewer mandatory repayments, while the company now carries a $400.0 million secured obligation.
New $400.0 million senior secured term loan matures November 2, 2031, with interest at three-month Term SOFR (1.00% floor) plus 5.50%, versus a fixed 15.0% rate paid in kind on the retired loans
Existing loans repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, which included a discount of about $68 million from the 2.0x MOIC payment
Minimum unrestricted cash covenant reduced to $125.0 million from $150.0 million
New agreement no longer requires prepayment from plozasiran sales, royalties, milestones or pipeline monetizations; the filing says the terms are to be filed with the 10-Q for the quarter ended December 31, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.